Leslie Z Benet

发表

The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.

Leslie Z Benet, L. Benet, 2013, Journal of pharmaceutical sciences.

Are There Any Experimental Perfusion Data that Preferentially Support the Dispersion and Parallel-Tube Models over the Well-Stirred Model of Organ Elimination?

Leslie Z Benet, Jasleen K Sodhi, Hong-Jaan Wang, 2020, Drug Metabolism and Disposition.

Predicting the extent of metabolism using in vitro permeability rate measurements and in silico permeability rate predictions.

Leslie Z Benet, L. Benet, Chelsea M Hosey, 2015, Molecular pharmaceutics.

Intestinal drug transporters: an overview.

Leslie Z Benet, L. Benet, G. Soveral, 2013, Advanced drug delivery reviews.

Effects of renal failure on drug transport and metabolism.

Hong Sun, Leslie Z Benet, L. Benet, 2006, Pharmacology & therapeutics.

Lead PK commentary: predicting human pharmacokinetics.

Leslie Z Benet, Malcolm Rowland, L. Benet, 2011, Journal of pharmaceutical sciences.

Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918.

Leslie Z Benet, Chi-Yuan Wu, L. Benet, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.

Leslie Z Benet, Chi-Yuan Wu, L. Benet, 2008, Advanced drug delivery reviews.

Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Tudor I. Oprea, Leslie Z Benet, Gabriele Cruciani, 2012, Advanced drug delivery reviews.

Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS).

Leslie Z Benet, L. Benet, Caroline A Larregieu, 2016, Chinese journal of natural medicines.

The drug transporter-metabolism alliance: uncovering and defining the interplay.

Leslie Z Benet, L. Benet, 2009, Molecular pharmaceutics.

Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development.

Leslie Z Benet, Brian Dean, L. Benet, 2013, Molecular pharmaceutics.

EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN

Hong Sun, Leslie Z Benet, L. Benet, 2004, Drug Metabolism and Disposition.

BDDCS class prediction for new molecular entities.

Tudor I. Oprea, Leslie Z Benet, Gabriele Cruciani, 2012, Molecular pharmaceutics.

BDDCS, the Rule of 5 and drugability.

Tudor I. Oprea, Oleg Ursu, Leslie Z Benet, 2016, Advanced drug delivery reviews.

Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System.

Leslie Z Benet, L. Benet, 2010, Basic & clinical pharmacology & toxicology.

Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems

Leslie Z Benet, L. Benet, Yong Huang, 2006, Journal of Pharmacology and Experimental Therapeutics.

In Vivo Modulation of Intestinal CYP3A Metabolism by P-Glycoprotein: Studies Using the Rat Single-Pass Intestinal Perfusion Model

Leslie Z Benet, L. Benet, L. Salphati, 2003, Journal of Pharmacology and Experimental Therapeutics.

Batch‐to‐Batch and Within‐Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence?

Leslie Z Benet, L. Benet, K. Carroll, 2019, Clinical pharmacology and therapeutics.

Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI

Leslie Z Benet, Rosa Chan, L. Benet, 2018, Toxicological sciences : an official journal of the Society of Toxicology.

Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics.

Leslie Z Benet, L. Benet, Maribel Reyes, 2011, Journal of pharmaceutical sciences.